[Organic anxiety disorder].
Shimoda
Kengo
K
Department of Neuropsychiatry, Nippon Medical School.
Kimura
Mahito
M
D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000175:diagnosis / Q000209:etiology / Q000523:psychology / Q000628:therapy; D001927:Brain Diseases / Q000150:complications; D015928:Cognitive Behavioral Therapy; D003937:Diagnosis, Differential; D039721:Diagnostic and Statistical Manual of Mental Disorders; D004700:Endocrine System Diseases / Q000150:complications; D006801:Humans; D038801:International Classification of Diseases; D054833:Isoindoles; D008659:Metabolic Diseases / Q000150:complications; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use
D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D054833:Isoindoles; D010879:Piperazines; D011743:Pyrimidines; D017366:Serotonin Receptor Agonists; C055267:tandospirone